Adiponectin levels have been observed to gradually decline in humans with NAFLD as the disease progresses, except when cirrhosis develops and hepatocytes fail to eliminate excess adiponectin [6]. The gene discussed is ADIPOQ; the disease is metabolic dysfunction-associated steatotic liver disease.